Sign in Subscribe
Genetic research

New Breakthrough in Personalized Medicine: Identifying Biomarkers for Colorectal Cancer

Strategic Insights

— 1 min read

Investigations by a team of researchers from the General Hospital of Southern Theater Command in Guangzhou, People's Republic of China, have led to a significant breakthrough in personalized medicine. The study, funded by the National Natural Science Foundation of China-guangdong Joint Fund and the Science And Technology Planning Project of Guangdong Province, aimed to identify circulating tumor DNA (ctDNA) methylation markers for early detection of cancer metastasis and to explore their impact on patient outcomes. According to the research, ZNF671 and ZNF132 methylation levels inversely correlate with Immunoscore and may serve as valuable biomarkers for colorectal cancer immunotherapy.

Key Takeaways:

  • The study analyzed 603 overlapping methylation markers from both plasma and tissue samples to develop a risk model for predicting colorectal cancer recurrence and prognosis.
  • ZNF671 and ZNF132 were identified as key methylation markers that inversely correlate with Immunoscore, a measure of the immune response in cancer patients.
  • The risk model predicted relapse risk in stage III colorectal cancer patients with an area under the curve (AUC) of 0.90 and prognosis in stage IV patients.
  • High-risk patients had a significantly higher early relapse rate (75.4% vs. 20%) and were more likely to have a low Immunoscore, which correlates with poorer prognosis.
  • The study's findings provide insights for improved prognostic evaluation and personalized treatment strategies for colorectal cancer patients.
  • The identified biomarkers may serve as valuable prognostic indicators for colorectal cancer and inform treatment decisions.

Statistics:

  • 603 overlapping methylation markers were analyzed in the study.
  • ZNF671 and ZNF132 methylation levels inversely correlated with Immunoscore.
  • The risk model predicted relapse risk in stage III colorectal cancer patients with an AUC of 0.90.
  • High-risk patients had a significantly higher early relapse rate (75.4% vs. 20%).
  • The study's findings provide insights for improved prognostic evaluation and personalized treatment strategies for 62,880 new cases of colorectal cancer diagnosed each year in the United States.

Sources:

  • "Combining the DNA methylation markers of circulating tumor cells with immune infiltrating cells to assess recurrence and prognosis and to suggest a therapeutic strategy in stage III-IV colorectal cancer". Frontiers in Immunology, 2025,16.
  • NewsRx. General Hospital of Southern Theater Command Researchers Focus on Personalized Medicine (Combining the DNA methylation markers of circulating tumor cells with immune infiltrating cells to assess recurrence and prognosis and to suggest a ...). Immunotherapy Weekly. August 13, 2025; p 2052.

Read more